TargetBeta
RRM1
ribonucleotide reductase catalytic subunit M1 · Ribonucleotide reductase subunits
2 programs in company-led studies act on RRM1, from 2 companies: 0 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Gemcitabinerule | Eli Lilly | phase 4 | 22434 running | RRM2, RRM2B | ChEMBL |
| Hydroxyurearule | Norgine | phase 4 | 152 running | RRM2, RRM2B | ChEMBL |
Conditions their studies are in
- Anemia, Sickle Cell, 1 program
- Biliary Tract Neoplasms, 1 program
- Breast Neoplasms, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Glioblastoma, 1 program
- HIV Infections, 1 program
- Neoplasms, 1 program
- Pancreatic Neoplasms, 1 program
- Polycythemia Vera, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026Gemcitabine · Eli Lilly · phase 4 · NCT06829823
- Feb 2028Hydroxyurea · Norgine · phase 4 · NCT06578507
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.